Merck’s Clark Affirms: “I Wouldn’t Rule Out Anything”
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is looking at “strategic opportunities.”
You may also be interested in...
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21
Mega-Merger Could Usher In New Era Of Consolidation
Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling